

Subawards Subcommittee

Jennifer Barron, Johns Hopkins University Amanda Hamaker, Purdue University Amanda Humphrey, Harvard University



- Updates/Suggested Template Changes
- Attachment 1 & 2 Updates
- Clinical Trial Subaward Template Update
- Foreign Subaward Template Update
- Guidance Documents Update
- RAQ Update



- Templates created to make things easier don't change them!
- Let us know if you get one with changes, we'll contact the institution.



• Fixed:

- Typos
- Grammatical inconsistencies
- Citation inconsistencies
- Format cleanup unique field names
- RTCs are no longer on the face page moved to attachment 2 since it is agency specific
- All template updates have been published EXCEPT: Facepage, Attachment 1 & 2. See email to listserv from April 29th for details.
- Have requests/updates? Email us!



Added use of name clause:

Use of Name Neither party shall use the other party's name, trademarks or other logos in any publicity, advertising, or news release, without the prior written approval of an authorized representative of that party. The parties agree that each party may respond to legitimate business inquiries with factual information regarding the existence and purpose of the relationship that is the subject of this Agreement, disclose such information to satisfy any reporting obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.



- Attachment 2 working group has resumed work on updates
- May 2016 revision of Attachment 2 posted to listserv for comment
- UG required data elements from face page moved to Attachment 2
 - e.g. federal award issue date, federal award amount to PTE, CFDA number and title, FAIN
- Reformatted the flow to accommodate the data moving from the facepage to Attachment 2.



- Items from previously suggested Compliance Attachment proposed to be added to Attachment 2
 - e.g. research subjects, data sharing, whistleblower
 - Feedback was that general assurance was duplicative with the assurances on the face page, so we revised to make one, more detailed assurance for the face page.
- Streamlined compliance language proposed, currently in review



- Removed export control language
 - Provided to the foreign working group since it would be more applicable there.
 - There will be an FAQ
- Streamlined RTC language to be more general



- Coming soon: "universal" Attachment 2!
- Features include:
 - Drop down sponsor pick list with pre-filled applicable flow downs
- Volunteers for this working group please contact Tyra Darville-Layne at td-layne@northwestern.edu



Clinical Trial Subaward Template

- Template complete!
- Approved by CTSI and NCATA
- Reviewed by NIH policy office, received comments
- Final should be released soon
- Once fixed price version is released, will work on cost reimbursement version



- Updated for UG
- There's more coming! Want to volunteer? Contact: Debra Brodlie dbrodlie@jhu.edu



- OMB guidance issued, provided clarification about some confusing fields.
- Want to volunteer? There's lots to do! Contact: Stephanie Scott Columbia University sfs2110@columbia.edu



OMB Clarifications/Technical Corrections

§200.331 (a) (vi) - Amount of Federal Funds Obligated by this action

by the pass-through entity to the subrecipient

Amount Funded This Action (both initial and amendments)



- PTE plans to issue a three-year research project of \$400,000 to a subrecipient,
 - \$100,000 per year for the first two years and
 - \$200,000 for the third year,
- The amount entered in the "Amount Funded This Action":
 - (original) subaward agreement: \$100,000;
 - year 2 (amendment) would be \$100,000; and
 - year 3 (amendment) would be \$200,000.



OMB Clarifications/Technical Corrections

§200.331 (a)(vii) Total Amount of Federal Funds Obligated to the subrecipient

by the pass-through entity including the current obligation

Total Amount of Federal Funds Obligated to Date (amendments)





- PTE plans to issue a three-year project of \$400,000 to a subrecipient at:
 - \$100,000 per year for first two years; and
 - \$200,000 for the third year.
- In year 2, if an Amendment is issued, \$200,000 would be indicated in *Total Amount of Federal Funds Obligated to Date* (for years 1 and 2).



OMB Clarifications/Technical Corrections

• §200.331 (a) (viii) Total Amount of the Federal Award

committed to the subrecipient by the pass-through entity

- According to OMB, "committed" is the planned, dedicated, or promised amount from the PTE to the subrecipient.
- Incrementally Estimated Total on the Face Page
- Don't need Total Amount of Fed Award to PTE.





- PTE plans to issue a three-year research project of \$400,000 to a subrecipient:
 - \$100,000 for first two years; and
 - \$200,000 for the third year.
- The *Incrementally Estimated Total* should be \$400,000.
- Many factors can impact actual future year awards.
- Don't be thrown by the word 'committed.' It has to do with 'planning,' as clarified by OMB.



"Action" = Now "Obligated" = To Date "Committed" = Estimated Total



- Working on an annual version of the RAQ
- ETA mid-late summer
- Come see us! NCURA annual meeting 1/2 day workshop on conducting risk assessments
- Want to volunteer? Contact Steve Carter, UCSD at <u>stevecarter@ucsd.edu</u>
- Have comments/suggestions about the RAQ? Email: <u>risk.assess.quest.fdp@gmail.com</u>



- Working groups continue their amazing work
 - Attachment 2
 - Compliance
 - Foreign
 - Guidance
- Starting a group to update the subcontract template. See me to volunteer.
- Other suggestions?